RZLT241220C5000
- 0.35
- 0.000.00%
Rezolute Newsroom
Rezolute, Inc. Advances Late-Stage Trials for Rare Disease Therapies
Is Rezolute, Inc. (RZLT) the Best Multibagger Stock to Buy Heading Into 2025?
We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully
Maxim Group Maintains Rezolute(RZLT.US) With Buy Rating, Announces Target Price $12
Rezolute Analyst Ratings
Wedbush Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $12
JMP Securities Maintains Rezolute(RZLT.US) With Buy Rating, Raises Target Price to $8
Rezolute's Promising Pipeline and Financial Stability Drive Buy Rating and Increased Price Target
Rezolute | 10-Q: Q1 2025 Earnings Report
Rezolute Q1 EPS $(0.22) Beats $(0.33) Estimate
Rezolute | 8-K: Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
Express News | Rezolute Inc: Phase 3 Sunrize Study on Track; U.S. Enrollment Expected to Commence in First Part of 2025
Express News | Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
Express News | Rezolute Q1 Income From Operations USD -16.941 Million
Press Release: Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
Wedbush Initiates Rezolute(RZLT.US) With Buy Rating, Announces Target Price $12
Rezolute to Participate in Upcoming Investor Conferences
Express News | Rezolute Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $12
AAO 2024: Rezolute's RZ-402 Shows Promising Phase IIa Results in DME Patients
With 62% Ownership, Rezolute, Inc. (NASDAQ:RZLT) Boasts of Strong Institutional Backing